Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Study protocol of the ACCESS trial: a randomised trial to evaluate the effectiveness of human papillomavirus testing by self-sampling in cervical cancer screening uptake and precancer detection.
Fujita M, Shimazu M, Nagashima K, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Shozu M, Hanaoka H, Tsuruoka N, Kasai T, Hata A. Fujita M, et al. Among authors: hanaoka h. BMJ Open. 2022 Feb 3;12(2):e049803. doi: 10.1136/bmjopen-2021-049803. BMJ Open. 2022. PMID: 35115348 Free PMC article.
Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Mitsuhashi A, Kawasaki Y, Hori M, Fujiwara T, Hanaoka H, Shozu M. Mitsuhashi A, et al. Among authors: hanaoka h. BMJ Open. 2020 Feb 28;10(2):e035416. doi: 10.1136/bmjopen-2019-035416. BMJ Open. 2020. PMID: 32114477 Free PMC article. Clinical Trial.
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial).
Aoyagi R, Hamada H, Sato Y, Suzuki H, Onouchi Y, Ebata R, Nagashima K, Terauchi M, Terai M, Hanaoka H, Hata A; KAICA Trial Investigators. Aoyagi R, et al. Among authors: hanaoka h. BMJ Open. 2015 Dec 1;5(12):e009562. doi: 10.1136/bmjopen-2015-009562. BMJ Open. 2015. PMID: 26628527 Free PMC article. Clinical Trial.
Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study.
Okonogi N, Usui H, Murata K, Hori M, Kurokawa T, Fujiwara T, Fujii Y, Hanawa M, Kawasaki Y, Hattori Y, Suzuki K, Tsuyuki K, Wakatsuki M, Hasegawa S, Yamada S, Hanaoka H, Shozu M, Tsuji H. Okonogi N, et al. Among authors: hanaoka h. BMJ Open. 2022 Mar 2;12(3):e056424. doi: 10.1136/bmjopen-2021-056424. BMJ Open. 2022. PMID: 35236732 Free PMC article.
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators. Hamada H, et al. Among authors: hanaoka h. Lancet. 2019 Mar 16;393(10176):1128-1137. doi: 10.1016/S0140-6736(18)32003-8. Epub 2019 Mar 7. Lancet. 2019. PMID: 30853151 Clinical Trial.
353 results